China's Akeso Says Its Cancer Drug Ivonescimab Outperformed AstraZeneca's Imfinzi in Phase 3 Trial for Biliary Tract Cancer
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug ivonescimab had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. Ivonescimab has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Robot baristas and K-pop dancers lead South Korea's physical AI boom
-
2
Goldman Sachs Strategists: Expect AI capital expenditure growth to slow in 2027, with earnings growth decelerating from 30% at that time.
-
3
Lookonchain: An anonymous trader gained over $1.05M in unrealized profit from a $2.9M STRK long position opened yesterday
-
4
Solidigm, a subsidiary of South Korean company SK Hynix, may list in the U.S. with a valuation of up to $150 billion.
-
5
Goldman Sachs Analysts: US Stock Bull Market "Only Has One Trade Left" – AI, Market Concentration Risk Intensifies
-
6
Al Jazeera Analysis: Gaza War Driving Israeli Politics Rightward, Extreme Rhetoric Increasing Ahead of Elections
-
7
London copper futures closed at $14,622 per ton on Friday, near historical highs; UBS reiterated its bullish stance, while JPMorgan Chase warned that strikes at Chilean copper mines could lead to production cuts.
-
8
Foreign ownership of Samsung Electronics falls to 18-year low of 46.37%, SK Hynix holdings also drop below 50%
-
9
Goldman Sachs Strategists: U.S. Stock Market Breadth Narrowest Since Dot-Com Bubble, But Expect Market to Rise by Year-End
-
10
NVIDIA is in talks to acquire U.S. AI startup Reflection AI, valued at $25 billion.
Markets Today
Recommended Reading


